These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23881998)

  • 1. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.
    Hoffman KB; Demakas A; Erdman CB; Dimbil M; Doraiswamy PM
    BMJ; 2013 Jul; 347():f4656. PubMed ID: 23881998
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment.
    Smith JR; Sacks S
    Int J Clin Pract; 2009 Apr; 63(4):596-605. PubMed ID: 19335705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports.
    Ueda N; Umetsu R; Abe J; Kato Y; Nakayama Y; Kato Z; Kinosada Y; Nakamura M
    Biol Pharm Bull; 2015; 38(10):1638-44. PubMed ID: 26424023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of oseltamivir during the 2009 influenza pandemic.
    Donner B; Bader-Weder S; Schwarz R; Peng MM; Smith JR; Niranjan V
    Pharmacoepidemiol Drug Saf; 2011 May; 20(5):532-43. PubMed ID: 21448900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
    Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oseltamivir- related psychiatric manifestations.
    Guisado-Macías JA; Rodríguez FF; Méndez-Sánchez F; Bolívar-Perálvarez M
    Actas Esp Psiquiatr; 2012; 40(1):46-8. PubMed ID: 22344496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oseltamivir for All: Should It Become an Over-the-Counter Medication for Influenza Treatment?
    Rech MA
    Pharmacotherapy; 2020 Mar; 40(3):182-185. PubMed ID: 32048321
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA
    Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
    [No Abstract]   [Full Text] [Related]  

  • 9. Postmarketing surveillance and reporting of adverse drug events.
    Baer RK
    S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
    [No Abstract]   [Full Text] [Related]  

  • 10. US Food and Drug Administration: adverse event reporting.
    Graham AA
    CRNA; 1998 Nov; 9(4):135-8. PubMed ID: 9866488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consumer groups look to improve adverse event reporting systems.
    Vastag B
    J Natl Cancer Inst; 2005 Dec; 97(24):1804-5. PubMed ID: 16368939
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 13. ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia.
    L'Huillier AG; Ing Lorenzini K; Crisinel PA; Rebsamen MC; Fluss J; Korff CM; Barbe RP; Siegrist CA; Dayer P; Posfay-Barbe KM; Desmeules JA;
    Pharmacogenomics; 2011 Oct; 12(10):1493-501. PubMed ID: 21902503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug effects: new information about an old problem.
    Miller CA
    Geriatr Nurs; 2001; 22(6):336-7. PubMed ID: 11780009
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuropsychiatric problems due to oseltamivir treatment in H7N9 bird flu.
    Wiwanitkit V
    Arq Neuropsiquiatr; 2014 Feb; 72(2):172. PubMed ID: 24604374
    [No Abstract]   [Full Text] [Related]  

  • 16. Oseltamivir: cutaneous and neurological adverse effects in children.
    Prescrire Int; 2006 Oct; 15(85):182-3. PubMed ID: 17128526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the MedDRA hierarchy on pharmacovigilance data mining results.
    Pearson RK; Hauben M; Goldsmith DI; Gould AL; Madigan D; O'Hara DJ; Reisinger SJ; Hochberg AM
    Int J Med Inform; 2009 Dec; 78(12):e97-e103. PubMed ID: 19230751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
    Ehrenpreis ED; Ciociola AA; Kulkarni PM;
    Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature.
    Raisch DW; Straight TM; Holodniy M
    Pharmacotherapy; 2009 Aug; 29(8):988-92. PubMed ID: 19637952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.